ArticleHematological oncology2022
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia.
Abstract readLetterComment
In one paragraph
Article in Hematological oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An overview of advanced nanocarrier systems for Ibrutinib delivery: overcoming pharmacokinetic barriers and enabling targeted cancer therapy.International journal of pharmaceutics: X · 2025Review
- Determining drug dose in the era of targeted therapies: playing it (un)safe?Blood cancer journal · 2022Review
Corrections and comments
- Comment on
Authors and funding
36 authors.
Gabriela ForestieriLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
Lodovico Terzi di BergamoLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
Marina DeodatoDepartment of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Anna Maria FrustaciDepartment of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.ORCID 0000-0003-2587-7901
Riccardo MoiaDepartment of Translational Medicine, Division of Hematology, University of Eastern Piedmont, Novara, Italy.ORCID 0000-0001-7393-1138
Clara DeambrogiDepartment of Translational Medicine, Division of Hematology, University of Eastern Piedmont, Novara, Italy.
Silvia RasiDepartment of Translational Medicine, Division of Hematology, University of Eastern Piedmont, Novara, Italy.
Francesco AutoreHematology Institute, Catholic University of the Sacred Hearth, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy.ORCID 0000-0002-7868-7469
Michele MerliOspedale di Circolo of Varese & Department of Medicine and Surgery, Hematology, ASST Sette Laghi, University of Insubria, Varese, Italy.ORCID 0000-0002-0905-5927
Roberta MattarucchiOspedale di Circolo of Varese & Department of Medicine and Surgery, Hematology, ASST Sette Laghi, University of Insubria, Varese, Italy.
Gaby FahrniDivision of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland.
Lydia Scarfo'Strategic Research Program on CLL, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy.
Daniela GussettiClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
Pietro BulianClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
Annagiulia ZanattaClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
Valeria SpinaLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
Alessio BruscagginLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
Katia PiniLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
Deborah PiffarettiLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
Maria Cristina PirosaLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
Matin SalehiLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
Joyce Marques de AlmeidaLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
Jakob PasswegClinic of Haematology, University Hospital Basel, Basel, Switzerland.
Franco CavalliInstitute of Oncology Research, Bellinzona, Switzerland.
Emanuele ZuccaClinic of Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.ORCID 0000-0002-5522-6109
Bernhard GerberClinic of Hematology, Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Georg StussiFaculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
Valter GatteiClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
Paolo GhiaStrategic Research Program on CLL, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy.
Michael GregorDivision of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland.
Francesco PassamontiOspedale di Circolo of Varese & Department of Medicine and Surgery, Hematology, ASST Sette Laghi, University of Insubria, Varese, Italy.
Luca LaurentiHematology Institute, Catholic University of the Sacred Hearth, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy.ORCID 0000-0002-8327-1396
Gianluca GaidanoDepartment of Translational Medicine, Division of Hematology, University of Eastern Piedmont, Novara, Italy.
Alessandra TedeschiDepartment of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.ORCID 0000-0001-8724-2771
Davide RossiLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.ORCID 0000-0002-2837-1597
Adalgisa CondoluciLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.ORCID 0000-0003-0483-5518
Funding
AstraZeneca Unrestricted Research Grant; Research Advisory Board of the Ente Ospedaliero Cantonale ABREOC 2019-22514European Research Council Consolidator Grant CLLCLONE 772051Swiss Cancer Research Foundation 3746Swiss Cancer Research Foundation 4395 4660Swiss Cancer Research Foundation 4705Swiss National Science Foundation 310030_192439Swiss National Science Foundation 320030_169670/1Swiss National Science Foundation 320036_179318
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Lymphocytic, Chronic, B-CellHumanschronic lymphocytic leukemiadose intensityibrutinib
Identifiers
PMID
35613703What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.